Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Casdatifan Tablet vs Capsule
NCT05999513Phase 1Completed
- Sponsor
- Arcus Biosciences
- Start
- Aug 2023
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of casdatifan in clear cell renal cell carcinoma (ccRCC) (3 arms), sponsored by Arcus Biosciences. Primary endpoints: Area Under the Plasma Drug Concentration-Time Curve, Maximum Concentration and 4 more. Started Aug 2023; status: completed.
02
Drugs
casdatifan
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT05999513.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05999513.